Overweight and cancer risk

Excess body weight is associated with elevated risk for at least 13 distinct cancer types, making obesity the second most common modifiable cause of cancer after tobacco use. The proposed connection involves excess adipose tissue driving hormonal imbalances, chronic low-grade inflammation, and altered metabolic signaling that collectively create conditions favorable to tumor development and spread. Colorectal, postmenopausal breast, endometrial, kidney, esophageal adenocarcinoma, and pancreatic cancers are among those most consistently implicated.

Adipose tissue is metabolically active and, when present in excess, secretes pro-inflammatory cytokines and adipokines, including leptin and interleukin-6, that can stimulate cancer cell proliferation and suppress programmed cell death. Elevated insulin and insulin-like growth factor-1 (IGF-1) signaling, common features of obesity, promote unchecked cell division and inhibit apoptosis across multiple tissue types. Aromatase enzymes embedded in fat tissue convert androgens to estrogens, raising circulating estrogen levels and increasing risk for hormone-sensitive cancers such as postmenopausal breast and endometrial cancer. Visceral adiposity, the accumulation of fat around internal organs, is increasingly recognized as more metabolically harmful than subcutaneous fat: computed tomography-derived visceral fat area appears to be a stronger predictor of cancer outcomes than body mass index (BMI) alone in some settings. Adipocytes can also directly shelter cancer cells from chemotherapy by secreting adipokines and activating autophagy, as demonstrated in multiple myeloma research.

A scoping review covering studies from 2004 to 2025 examined the relationship between obesity and glioma, a cancer type not classically linked to excess weight, and found evidence suggesting a modest association, though the authors note that a comprehensive analysis had not previously been conducted. Research on breast cancer found that extracellular vesicles secreted by adipose tissue from individuals with obesity can modulate tumor cell behavior in MCF-7 breast cancer cells, pointing to a biological pathway through which excess fat may drive greater metastatic potential. A retrospective cohort study of gastric cancer patients found that visceral fat area predicted overall survival after curative gastrectomy more reliably than BMI, with age further modifying these relationships. In a Korean cohort of over 85,000 participants, the Chinese Visceral Adipose Index showed meaningful predictive ability for gastric intestinal metaplasia, a recognized precancerous lesion. Evidence from bariatric surgery studies indicates that sustained weight reduction of 20 to 30 percent in people with severe obesity is associated with reduced risk of obesity-related cancers over 10 years, offering some of the strongest available signals that weight itself, not merely associated behaviors, influences cancer risk. A randomized clinical trial of a fully automated web-based dietary intervention (the AMPLIFY trial) among cancer survivors who were overweight or obese demonstrated that structured diet programs are feasible in this population, though whether such interventions reduce subsequent cancer events remains under investigation.

The relationship between obesity and cancer risk is not uniform across cancer types or populations. Postmenopausal women face heightened risk for estrogen-driven cancers, including breast and endometrial cancers, partly because fat tissue becomes the dominant site of estrogen production after menopause, amplifying the effect of excess adiposity. Paradoxically, in some cancer types such as lung cancer, individuals with obesity have shown improved survival compared to leaner counterparts, a phenomenon sometimes described as the obesity paradox, which may reflect differences in metabolic reserve or immune function rather than a genuinely protective effect of excess fat. Visceral fat distribution appears to matter more than total weight for several cancer risk and prognosis measures, meaning that two people with identical BMI values may carry meaningfully different risk depending on where fat accumulates. Rising rates of early-onset colorectal cancer (diagnosed before age 50) are increasingly attributed in part to higher rates of obesity among younger generations.

Most evidence linking obesity to cancer risk comes from large observational studies, including prospective cohort studies and meta-analyses, which can identify strong associations but are subject to confounding by diet quality, physical activity, and socioeconomic factors. The causal link between excess body weight and increased cancer incidence is considered well-established for approximately 13 cancer types by major health agencies, grounded in decades of epidemiological data and supported by plausible biological mechanisms. Evidence is strongest for colorectal, postmenopausal breast, endometrial, kidney, and esophageal adenocarcinoma. Emerging areas of investigation include the role of glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, as potential cancer risk modifiers: these drugs produce substantial weight loss and may also directly reprogram the tumor immune microenvironment, though randomized trial data focused specifically on cancer incidence are not yet available. Mendelian randomization studies are increasingly being used to disentangle causal effects from confounding, including in the context of BMI and hormone-sensitive cancer risk.

The evidence consistently suggests that excess body weight is a meaningful and modifiable contributor to cancer risk across a range of cancer types, though the strength and nature of that relationship vary by cancer type, body fat distribution, sex, and age. Research increasingly points to visceral adiposity, rather than BMI alone, as a more informative marker, suggesting that measures beyond simple weight may be relevant to understanding individual risk. Whether intentional weight loss through diet, physical activity, or newer pharmacological approaches translates directly into reduced cancer incidence remains an active area of investigation, with bariatric surgery studies offering the most compelling signals to date.